Page last updated: 2024-12-08

l 659066

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vatinoxan: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163952
CHEMBL ID4298165
SCHEMBL ID9866468
MeSH IDM0156724

Synonyms (29)

Synonym
114914-42-0
l 659066
SCHEMBL9866468
n-[2-[(2r,12bs)-2'-oxospiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,5'-imidazolidine]-1'-yl]ethyl]methanesulfonamide
l-659,066
unii-342eyn0qfd
methanesulfonamide, n-(2-(1,3,4,6,7,12b-hexahydro-2'-oxospiro(2h-benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl)-, trans-
342eyn0qfd ,
vatinoxan
mk 467
vatinoxan [inn]
l-659066
methanesulfonamide, n-(2-(1,3,4,6,7,12b-hexahydro-2'-oxospiro(2h-benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl)-, (2r-trans)-
vatinoxan [usan]
methanesulfonamide, n-(2-((2r,12bs)-1,3,4,6,7,12b-hexahydro-2'-oxospiro(2h-benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl)-
mk-467 free base
n-(2-((2r,12bs)-2'-oxo-1,3,4,6,7,12bhexahydrospiro((1)benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl)methanesulfonamide
GTBKISRCRQUFNL-OXJNMPFZSA-N
n-(2-((2r,12bs)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4'-imidazolidine]-3'-yl)ethyl)-methanesulfon-amide
DTXSID80921542
n-[2-(2'-hydroxy-1,3,4,6,7,12b-hexahydrospiro[1-benzofuro[2,3-a]quinolizine-2,4'-imidazol]-3'(5'h)-yl)ethyl]methanesulfonamide
n-{2-[(2r,12bs)-2'-oxo-1,3,4,6,7,12bhexahydrospiro[[
1]benzofuro[2,3-a]quinolizine-
2,4'-imidazolidin]-3'-yl]ethyl}methanesulfonamide
D11320
vatinoxan (usan)
Q27256320
CHEMBL4298165
AKOS040749743

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Antagonism by MK-467 of medetomidine-evoked vasoconstriction is seen as the mechanism behind this pharmacokinetic drug interaction."( Effects of MK-467 on the antinociceptive and sedative actions and pharmacokinetics of medetomidine in dogs.
Bennett, RC; Hänninen, L; Raekallio, MR; Rinne, VM; Salla, KM; Scheinin, M; Vainio, OM, 2016
)
0.43
" Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14."( Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats.
Honkavaara, J; Ilkiw, JE; Pypendop, BH, 2016
)
0.43
"To investigate the effects of MK-467 on sedation quality, and cardiopulmonary and pharmacokinetic variables in horses sedated intravenously (IV) with romifidine."( Clinical effects and pharmacokinetic variables of romifidine and the peripheral α
de Vries, A; Ekiri, A; Pakkanen, SA; Raekallio, MR; Scheinin, M; Taylor, PM; Vainio, OM, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" PROCEDURES In a randomized crossover study, each dog received 5 premedication protocols (medetomidine [10 μg/kg, IV] alone [MED] and in combination with MK-467 at doses of 50 [MMK50], 100 [MMK100], and 150 [MMK150] μg/kg and 15 minutes after glycopyrrolate [10 μg/kg, SC; MGP]), with at least 14 days between treatments."( Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane.
Bennett, RC; Kuusela, E; Raekallio, MR; Salla, KM; Scheinin, M; Tuns, CI; Vainio, OM, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The dosage of MK-467 needs to be investigated to minimise the effect of MK-467 on MAP."( Detomidine and the combination of detomidine and MK-467, a peripheral alpha-2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane.
de Vries, A; Mykkänen, AK; Pakkanen, SA; Raekallio, MR; Salla, KM; Scheinin, M; Vainio, OM; Vuorilehto, L, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.56)18.7374
1990's12 (15.38)18.2507
2000's6 (7.69)29.6817
2010's42 (53.85)24.3611
2020's16 (20.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.01 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index5.79 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (50.63%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (49.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]